UBS raised the firm’s price target on Ardent Health (ARDT) to $13.50 from $13 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health Earnings Call Highlights Margin Momentum
- Ardent: Solid Q1 Beat but Conservative 2026 Outlook Keeps Rating at Hold
- Ardent: Solid Q1 and Reaffirmed 2026 Outlook Support Hold Rating as $12 Price Target Remains Unchanged
- Ardent Health price target lowered to $13 from $15 at Guggenheim
- Ardent Health Announces Leadership Change in Hospital Services